Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ctxt Pty Ltd. currently has a specific prosecution footprint within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which represents the total active workload for the company. This matter is being reviewed by 1 distinct examiner, showing that the company's current patent office interactions are limited to a specific point of review. This suggests a targeted strategy for its current biotechnology innovations.
The prosecution is occurring within 1 distinct art unit, indicating a focused technical application of its research. FETTEROLF, BRANDON J is the busiest examiner for the portfolio, managing 1 busiest examiner pending office action. As this is the only 1 pending office action in the portfolio, the examiner's decisions will have an impact on the company's current prosecution success. Practitioners should note that with only 1 distinct examiner and 1 distinct art unit involved, the prosecution timeline and results are dependent on the specific procedures of this office location.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18903849 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | SHOWALTER, ALEXANDER KEITH | — |
| 18016070 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903849 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | SHOWALTER, ALEXANDER KEITH | — | §103§112DP | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18016070 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | FETTEROLF, BRANDON J | 1629 | DP | Final Rejection | — | Pending |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial